Data on the antimicrobial activity of XF-73 against bacteria within biofilms to be presented at prestigious 2022 ECCMID Congress
Brighton, United Kingdom – 31 March 2022 – Destiny Pharma plc (AIM:DEST), a clinical stage biotechnology company focused on the development of novel medicines to prevent life threatening infections, today announces that an abstract providing data on the antimicrobial activity of XF-73 against bacteria within biofilms has been accepted for presentation at Europe’s premier antimicrobials congress, the 32nd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), to be held 23- 26 April, 2022. The data were generated as part of a research collaboration with Aston University.
Presentation Title: Antibacterial efficacy of XF-73 via two mechanisms of action against Gram-positive microorganisms in biofilm mode of growth
Presenting Author: Isabella Romeo-Melody
Abstract #: 04656
Session: Preclinical biofilm studies
Session code: 9c
ECCMID is the world’s premier Clinical Microbiology & Infectious Diseases event, bringing together experts from many fields to present their latest findings, and developments and share their expertise.
XF-73 is the lead drug candidate from Destiny Pharma’s XF platform, initially being developed for the prevention of post-surgical staphylococcal infections, such as methicillin-resistant Staphylococcus aureus (MRSA), which cause significant complications and increased healthcare costs in the hospital setting. XF-73 has been awarded both Qualified Infectious Disease Product (QIDP) and Fast Track status by the US FDA.
Full PR available here